Sail Biomedicines, Inc. ("Sail"), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Laura Sepp-Lorenzino, Ph.D., has joined its Board of Directors. Dr.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept ...

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its target price lifted by Piper Sandler from $128.00 to $131.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Learn more about whether Corcept Therapeutics Incorporated or Sanofi is a better investment based on AAII's A+ Investor ...

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. And retail traders should ...

Menlo Park-based Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay ...